


augusta

About us:

Augusta was formed in 2002 as Sky Pharmaceuticals (Zambia) limited. **Augusta pharmaceuticals** has earned a reputable household name for housing the industry's most extensive and specialized services & specializes in the supply of pharmaceuticals drugs, medical devices, medical equipment's and other medical consumables. Our endeavor is to reach & provide the best services to further empower the medical institutions in our nations

Augusta is a part of the **Avacare Health Group** , Avacare Health is an integrated healthcare group serving the African region and beyond, The inception of **Avacare Health** was done in 1996 with the vision to make a difference to the people of Africa.

Our panoramic approach enables us to focus on a wider Out-reach while maintaining the quality of our service including installations, training, maintenance & product delivery






provides **Integrated Innovative & Holistic Health Solutions** in

Various Disciplines

&

Key Partners



augusta 

with


innovata
pharmaceuticals
an avacarehealth company

Presents to You

Avacort-BF

Budesonide 100 mcg + Formoterol 6 mcg
Budesonide 200 mcg + Formoterol 6 mcg
Budesonide 400 mcg + Formoterol 12 mcg



Now Available for the **First Time in Zambia...**



**Improper Use of Asthma Inhaler
Device is associated with.....**

.....Poor Asthma Control¹

&

More frequent Emergency Department Visits¹

In treatment of Asthma

Avacort-BF

Budesonide 100 mcg + Formoterol 6 mcg
Budesonide 200 mcg + Formoterol 6 mcg
Budesonide 400 mcg + Formoterol 12 mcg

“The Patented Device”

Which offers
Ease of Use¹

Higher Preference³
& Greater Patient
Satisfaction¹



Demonstrates
Lowest Number of
Critical Handling
Errors¹

Backed with
Extensive Real World Clinical Evidence¹

In treatment of Asthma,

Avacort-BF

Budesonide 100 mcg + Formoterol 6 mcg
Budesonide 200 mcg + Formoterol 6 mcg
Budesonide 400 mcg + Formoterol 12 mcg

GINA* guideline recommends ICS# – Formoterol in Asthma
As Preferred Controller & Reliever to Reduce Risk of Serious Exacerbations & Control of Symptoms¹

Budesonide/formoterol delivered via the Avacort-BF Elpenhaler[®]

Offers Ease of Use



- **Easy to use** - Does not require coordination between inhalation & device actuation unlike Pressurized Metered Dose Inhalers (pMDI)²
- **Easy to count** remaining dose by counting the Strips²
- **Unique dual verification** – Visual & Taste for dose uptake²



1. Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention, 2022. Available from : www.ginasthma.org
2. Bouros D. et al., J Pulm Respir Med 2016, 6:4

*GINA – Global Initiative for Asthma, #ICS - Inhaled Corticosteroids, DPIs ** - Dry Powder Inhalers

In treatment of Asthma,

Avacort-BF

Budesonide 100 mcg + Formoterol 6 mcg
Budesonide 200 mcg + Formoterol 6 mcg
Budesonide 400 mcg + Formoterol 12 mcg

GINA* guideline recommends ICS# – Formoterol in Asthma
As Preferred Controller & Reliever to Reduce Risk of Serious Exacerbations & Control of Symptoms¹

Budesonide/formoterol delivered via the Avacort-BF Elpenhaler[®]

According to,

Critical Steps Real Life Study - Compared to other DPIs** devices²



Demonstrates Lowest Number of Critical Handling Errors²

Offers better adherence to therapy...Leads to improved disease control²



1. Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention, 2022. Available from : www.ginasthma.org
2. Bouros D. et al., J Pulm Respir Med 2016, 6:4

*GINA – Global Initiative for Asthma, #ICS - Inhaled Corticosteroids, DPIs ** - Dry Powder Inhalers

In treatment of Asthma,

Avacort-BF

Budesonide 100 mcg + Formoterol 6 mcg
Budesonide 200 mcg + Formoterol 6 mcg
Budesonide 400 mcg + Formoterol 12 mcg

GINA* guideline recommends ICS# – Formoterol in Asthma
As Preferred Controller & Reliever to Reduce Risk of Serious Exacerbations & Control of Symptoms¹

Budesonide/formoterol delivered via the Avacort-BF Elpenhaler[®]

According to,

PAIR - Real Life Study - Compared to other DPIs** devices



Has Higher Preference²



1. Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention, 2022. Available from : www.ginasthma.org
2. Karampitsakos et al. Pulmonary Pharmacology & Therapeutics (2020)

*GINA – Global Initiative for Asthma, #ICS - Inhaled Corticosteroids, DPIs ** - Dry Powder Inhalers

In treatment of Asthma,

Avacort-BF

Budesonide 100 mcg + Formoterol 6 mcg
Budesonide 200 mcg + Formoterol 6 mcg
Budesonide 400 mcg + Formoterol 12 mcg

GINA* guideline recommends ICS# – Formoterol in Asthma
As Preferred Controller & Reliever to Reduce Risk of Serious Exacerbations & Control of Symptoms¹

Budesonide/formoterol delivered via the Avacort-BF Elpenhaler[®]

According to,

ANASA Real Life Study - Compared to other DPIs** devices



Has Greater Patient Satisfaction²

Consistent Higher Score in FSI^{##}10–Questionnaire²



1. Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention, 2022. Available from : www.ginasthma.org
2. Zervas et al. Intern. J. COPD, 2016; 11:1845-1855

In treatment of Asthma

Avacort-BF

Budesonide 100 mcg + Formoterol 6 mcg
Budesonide 200 mcg + Formoterol 6 mcg
Budesonide 400 mcg + Formoterol 12 mcg

GINA* guideline recommends ICS# – Formoterol in Asthma
As Preferred Controller & Reliever to Reduce Risk of Serious Exacerbations & Control of Symptoms

Budesonide/formoterol delivered via the Avacort-BF Elpenhaler®



Avacort-BF Elpenhaler® -Backed with Extensive Clinical Research Studies¹



Elpenhaler® Evidence from Real life Studies

1. CRITICAL STEPS STUDY	2. ANASA STUDY
3. PAIR STUDY	4. AEOLOS STUDY
5. BOREAS STUDY	6. COMPLETE STUDY
7. RETRIEVE STUDY	8. SKIRON STUDY
9. AHEAD STUDY	

- ✓ 12 publications in peer reviewed journals
- ✓ >31 posters in European conferences
- ✓ 3 oral presentations in International conferences (WAM-ERS)



*GINA – Global Initiative for Asthma, #ICS - Inhaled Corticosteroids, DPIs ** - Dry Powder Inhalers

Our Cardiac Range



In

- Treatment of Deep Vein Thrombosis (DVT) & Pulmonary Embolism (PE)
- Prevention of recurrent Deep Vein Thrombosis (DVT) and recurrent Pulmonary Embolism (PE)
- Prophylaxis of DVT undergoing knee or hip replacement surgery & nonmajor orthopaedic surgery
- Prophylaxis of Venous Thromboembolism (VTE) in acutely ill medical patients

Presenting,

Rivar

Rivaroxaban 10 mg Tablets
Rivaroxaban 15 mg Tablets
Rivaroxaban 20 mg Tablets

Predictable pharmacokinetics and pharmacodynamics compared to Warfarin¹

- No need for laboratory monitoring
- Wide therapeutic window
- Low drug–drug and food interactions - No dietary restriction
- No risk for induced skin necrosis due to rapid onset – can be initiated without LMWH
- Effective, safe, single-drug approach to the initial and continued treatment of Venous Thrombosis²
- Predictable pharmacokinetics and pharmacodynamics relative to warfarin¹




1. Mekaj YH, et al. Ther Clin Risk Manag. 2015 Jun 24; 11:967-77.

2. EINSTEIN Investigators, Bauersachs R, et al. N Engl J Med. 2010 Dec 23; 363(26):2499-510.

**As first-line treatment, or for patients whose BP is not adequately controlled
with Amlodipine alone**

Amlotel

Telmisartan 40 mg + Amlodipine 5 mg Tablets
Telmisartan 40 mg + Amlodipine 10 mg Tablets
Telmisartan 80 mg + Amlodipine 5 mg Tablets
Telmisartan 80 mg + Amlodipine 10 mg Tablets





Amlotel

Telmisartan 40 mg + Amlodipine 5 mg Tablets
 Telmisartan 40 mg + Amlodipine 10 mg Tablets
 Telmisartan 80 mg + Amlodipine 5 mg Tablets
 Telmisartan 80 mg + Amlodipine 10 mg Tablets

Fixed Dose Combination provides

- Complementary and synergistic mode of action¹
- Significantly greater double-digit BP reductions than amlodipine monotherapy¹
- Majority of the BP reduction observed within the first 2 weeks of treatment²
- Improved tolerability ensures patient compliance³
- Effective across hypertensive populations including those with high CV risk⁴



1. TEAMSTA-5 and TEAMSTA-10 Studies : Current Therapeutic Research 2012; 73 (1-2): 65-84

2. Postgrad Med. 2009;121(2):5-14

3. J Clin Hypertens (Greenwich). 2011;13:459-466

4. J Clin Hypertens (Greenwich). 2012;14(4):206-215

**In stage 2 hypertensives with high risk of stroke and MI
In hypertensive patients with stroke, uncontrolled on monotherapy**

Valvasc
Valsartan 160 mg + Amlodipine 5 mg Tablets
Valsartan 160 mg + Amlodipine 10 mg Tablets

Protects against cardiovascular and renal Morbidity & Mortality

**Indicated in hypertensives
uncontrolled on monotherapy or
patients stabilized on valsartan and
amlodipine as separate drugs**



In stage 2 hypertensives with high risk of stroke and MI
In hypertensive patients with stroke, uncontrolled on monotherapy

Valvasc
Valsartan 160 mg + Amlodipine 5 mg Tablets
Valsartan 160 mg + Amlodipine 10 mg Tablets

Gain the benefits of 2 highly effective and well-tolerated antihypertensives

Valsartan & Amlodipine as individual drugs given as monotherapy:

- Reduces cardiac morbidity and mortality
- Lowers fatal strokes and non-fatal strokes & MI
- Reduces the risk of hospitalizations for heart failure
- Powerful BP lowering with dual action
- Favourable safety profile



Patients with high risk of CVD*

Rx
Cardiz Co

Telmisartan 40 mg + Hydrochlorothiazide 12.5 mg Tablets
Telmisartan 80mg + Hydrochlorothiazide 12.5 mg Tablets

Provides higher BP control rates

Indicated in patients whose blood pressure has been stabilized at the same dosage of the individual components given together

- Provides higher BP control
- Efficacious in a wide variety of patient subpopulations
- Well tolerated in hypertensive patients with CV risk
- Improves treatment adherence

For  24 hr - BP control

Rx
Cardiz

Telmisartan 40 mg Tablet
Telmisartan 80 mg Tablet

**Benefits beyond optimal blood pressure control...
cardioprotective effect**

Indicated for the treatment of mild to moderate hypertension, either alone or in combination with hydrochlorothiazide

- Unique features compared to other ARBs
- Ensures sustained BP control
- Benefits beyond BP control
- Reduces CV risk
- Backed with strong clinical evidence

Our Pain Management Brand

Pain Control
from **24** Minutes* to **24** Hours



- Osteoarthritis (OA)
- Acute Gouty arthritis
- Rheumatoid arthritis (RA)
- Primary Dysmenorrhea



Rx
Etoflam

Etoricoxib 60 mg Tablet
 Etoricoxib 90 mg Tablet
 Etoricoxib 120 mg Tablet

Pain Control
 from **24** Minutes* to **24** Hours

Offer distinct advantages

- Rapid onset of action (approx. 24 min)¹
- Long Half-life - Convenient once-daily regimen²
- Most selective COX-2-selective inhibitors²
- Lower rates of discontinuations due to GI adverse effects¹
- Comparable CV risk with traditional NSAIDs^{2,}



Thank you!